Receptor Tyrosine Kinases : Structure, Functions and Role in Human Disease (Reprint) (Paperback)

Receptor Tyrosine Kinases : Structure, Functions and Role in Human Disease (Reprint) (Paperback)

AZD2171, a Pan-VEGF Receptor Tyrosine Kinase Inhibitor, Normalizes Tumor Vasculature and Alleviates Edema in Glioblastoma Patients: Cancer Cell

AZD2171, a Pan-VEGF Receptor Tyrosine Kinase Inhibitor, Normalizes Tumor Vasculature and Alleviates Edema in Glioblastoma Patients: Cancer Cell

Cellular Landscapes: Receptor Tyrosine Kinase (RTK)

Cellular Landscapes: Receptor Tyrosine Kinase (RTK)

Graphene radio frequency receiver integrated circuit : Nature Communications : Nature Publishing Group

Graphene radio frequency receiver integrated circuit : Nature Communications : Nature Publishing Group

Regorafenib (BAY 73-4506, commercial name Stivarga) is an oral multi-kinase inhibitor developed by Bayer which targets angiogenic, stromal and oncogenic receptor tyrosine kinase (RTK).

Regorafenib (BAY 73-4506, commercial name Stivarga) is an oral multi-kinase inhibitor developed by Bayer which targets angiogenic, stromal and oncogenic receptor tyrosine kinase (RTK).

Access : Tyrosine kinase receptors as molecular targets in pheochromocytomas and paragangliomas : Modern Pathology

Access : Tyrosine kinase receptors as molecular targets in pheochromocytomas and paragangliomas : Modern Pathology

Sunitinib (Sutent) is a multi-targeted receptor tyrosine kinase (RTK) inhibitor for the treatment of renal cell carcinoma (RCC) and imatinib-resistant gastrointestinal stromal tumor (GIST). Sunitinib was the first cancer drug simultaneously approved for two different indications. Sunitinib inhibits cellular signaling by targeting multiple receptor tyrosine kinases (RTKs).  These include all PDGF-Rs and VEGFRs, which play a role in both tumor angiogenesis and tumor cell proliferation.

Sunitinib (Sutent) is a multi-targeted receptor tyrosine kinase (RTK) inhibitor for the treatment of renal cell carcinoma (RCC) and imatinib-resistant gastrointestinal stromal tumor (GIST). Sunitinib was the first cancer drug simultaneously approved for two different indications. Sunitinib inhibits cellular signaling by targeting multiple receptor tyrosine kinases (RTKs). These include all PDGF-Rs and VEGFRs, which play a role in both tumor angiogenesis and tumor cell proliferation.

AZD2171, a Pan-VEGF Receptor Tyrosine Kinase Inhibitor, Normalizes Tumor Vasculature and Alleviates Edema in Glioblastoma Patients: Cancer Cell

AZD2171, a Pan-VEGF Receptor Tyrosine Kinase Inhibitor, Normalizes Tumor Vasculature and Alleviates Edema in Glioblastoma Patients: Cancer Cell

schematic representation of various receptor tyrosine kinase (RTK) sub-types

schematic representation of various receptor tyrosine kinase (RTK) sub-types

Pinterest
Search